Antibody Characterization

Antibody Characterization 


Our company has extensive experience in the characterization and formulation of monoclonal and bispecific antibodies for research, diagnostic, and therapeutic applications.
  • Antibody characterization: We use a range of techniques to characterize the quality and performance of antibodies, including identity, purity, content and activity by methods such as protein chip bioanalyzer (SDS-PAGE), UV spectroscopy, DLS, nDSF, IEF, and ELISA.  
  • We have experience in lyophilization and formulation development of novel antibody formats, including antibody drug conjugates (ADCs), bi-specific antibodies, and monoclonal antibodies.

What are antibodies?

  1. Monoclonal antibodies: These are produced from a single clone of cells, and are characterized by their high specificity and affinity for a particular target. Monoclonal antibodies are commonly used as research tools, diagnostics, and therapeutics.
  2. Humanized antibodies: These are produced by engineering non-human antibodies to have human-like properties, and are characterized by their reduced immunogenicity and increased pharmacokinetic properties. Humanized antibodies are commonly used as therapeutics.
  3. Chimeric antibodies: These are produced by combining the variable regions of a non-human antibody with the constant regions of a human antibody, and are characterized by their ability to retain the specificity of the non-human antibody while minimizing immunogenicity. Chimeric antibodies are commonly used as therapeutics.
  4. Bispecific antibodies: These are produced by engineering antibodies to bind to two different targets simultaneously, and are characterized by their ability to bridge two immune cells or two different epitopes on the same cell. Bispecific antibodies are being developed as therapeutics for cancer and other diseases.
  5. Antibody drug conjugates (ADCs): These are produced by conjugating a cytotoxic drug to an antibody, and are characterized by their ability to selectively deliver the drug to target cells. ADCs are being developed as therapeutics for cancer and other diseases.